Novartis Ag (NVSEF) Current Deferred Revenue (2017 - 2020)

Novartis Ag (NVSEF) has 4 years of Current Deferred Revenue data on file, last reported at $56.0 million in Q4 2020.

• Quarterly Current Deferred Revenue fell 50.88% year-over-year to $56.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $56.0 million (down 50.88% YoY) and the FY2020 annual result came in at $56.0 million, down 50.88% from the prior year.
• Current Deferred Revenue slipped to $56.0 million in Q4 2020 per NVSEF's latest filing, from $114.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $305.0 million in Q4 2017, with the low at $56.0 million in Q4 2020.
• Average Current Deferred Revenue over 4 years is $177.8 million, with a median of $175.0 million recorded in 2018.
• Year-over-year, Current Deferred Revenue retreated 22.62% in 2018 and sank 51.69% in 2019.
• Novartis Ag's Current Deferred Revenue stood at $305.0 million in 2017, then fell by 22.62% to $236.0 million in 2018, then slumped by 51.69% to $114.0 million in 2019, then plunged by 50.88% to $56.0 million in 2020.
• Business Quant data shows NVSEF's Current Deferred Revenue at $56.0 million in Q4 2020, $114.0 million in Q4 2019, and $236.0 million in Q4 2018.